Lack of Rab27a attenuates foam cell formation and macrophage inflammation in uremic apolipoprotein E knockout mice

Shen, Yan; Gao, Yajuan; Fu, Jiao; Wang, Cui; Tang, Yali; Chen, Shengnan; Zhao, Yan

doi:10.1007/s10735-023-10125-w

J Mol Histol

2023

DOI: 10.1007/s10735-023-10125-w

|View full text |Cite|

Lack of Rab27a attenuates foam cell formation and macrophage inflammation in uremic apolipoprotein E knockout mice

Yan Shen

Yajuan Gao

Jiao Fu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment

Sun,

Jia,

Tan

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Atherosclerosis (AS) is the formation of atherosclerotic plaques on the walls of the arteries, causing them to narrow. If this occurs in the coronary arteries, the blood vessels may be completely blocked, resulting in myocardial infarction; if it occurs in the blood vessels of the brain, the blood vessels may be blocked, resulting in cerebral infarction, i.e., stroke. Studies have shown that the pathogenesis of atherosclerosis involves the processes of inflammation, lipid infiltration, oxidative stress, and endothelial damage, etc. SIRT, as a key factor regulating the molecular mechanisms of oxidative stress, inflammation, and aging, has an important impact on the pathogenesis of plaque formation, progression, and vulnerability. Statistics show that AS accounts for about 50 per cent of deaths in Western countries. Currently, oral medication is the mainstay of AS treatment, but its development is limited by side effects, low bioavailability and other unfavourable factors. In recent years, with the rapid development of nano-preparations, researchers have combined statins and natural product drugs within nanopreparations to improve their bioavailability. Based on this, this paper summarises the main pathogenesis of AS and also proposes new oral nanoformulations such as liposomes, nanoparticles, nanoemulsions, and nanocapsules to improve their application in the treatment of AS.

show abstract

Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment

Sun,

Jia,

Tan

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lack of Rab27a attenuates foam cell formation and macrophage inflammation in uremic apolipoprotein E knockout mice

Cited by 1 publication

References 47 publications

Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment

Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment

Contact Info

Product

Resources

About